GlassScriptPhysician profile
Gregory A Parker
NPI 1851392575
$12,250.47
in general payments reported to CMS, 2019-2025
57 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $1,181 · 2021: $2,010 · 2022: $1,897 · 2023: $2,124 · 2024: $1,837 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,759.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,382.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,313.88 | 2019-2025 | |
| Lilly USA, LLC | $955.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $921.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $723.80 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $621.63 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $570.25 | 2022-2025 | |
| Pfizer INC. | $567.89 | 2019-2025 | |
| Amgen INC. | $539.58 | 2019-2025 | Repatha, Otezla, Evenity |
| Eisai INC. | $349.84 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $289.70 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $285.80 | 2019-2022 | |
| Ardelyx, INC. | $279.06 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.54 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $212.79 | 2019-2022 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $208.02 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $207.39 | 2024-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $205.09 | 2020-2023 | Nexletol |
| Daiichi Sankyo INC. | $192.93 | 2024-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.65 | 2021-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $164.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $144.69 | 2019-2022 | |
| Axsome Therapeutics, INC. | $140.89 | 2023-2024 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $131.22 | 2021 | |
| Allergan, INC. | $118.79 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $107.81 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $101.46 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $100.28 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Mylan Specialty L.P. | $99.45 | 2022-2024 | Yupelri |
| Horizon Therapeutics Plc | $84.05 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $62.37 | 2023 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $52.99 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $46.65 | 2021 | |
| Halozyme INC | $44.06 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $42.41 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.33 | 2021-2024 | Eliquis |
| Irhythm Technologies, INC. | $32.54 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Idorsia Pharmaceuticals US INC | $31.58 | 2022-2023 | Quviviq |
| Medtronic, INC. | $31.10 | 2025 | Venaseal |
| Dexcom, INC. | $30.44 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $29.42 | 2023 | Belbuca |
| Aytu Biopharma, INC. | $26.85 | 2020 | |
| Mannkind Corporation | $21.86 | 2024 | |
| Viatris Specialty LLC | $21.36 | 2025 | Yupelri |
| Therapeuticsmd, INC. | $20.42 | 2019 | |
| Hikma Pharmaceuticals USA | $18.76 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.09 | 2024 | Voquezna |
| Corium, LLC | $17.98 | 2022 | |
| Vanda Pharmaceuticals INC. | $17.52 | 2025 | Fanapt |
| Seqirus USA INC | $16.76 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Adlon Therapeutics L.P. | $16.39 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.29 | 2021 | |
| Sanofi Pasteur INC. | $14.14 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $13.86 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.81 | 2024 | Nuzyra |
| Vivus LLC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.